Change over period: —
NSE · GLAXO
GLAXOSMITH
-15.1% from the 52-week high · +25.4% above the low
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 3,680 full-time employees. The firm is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. The company manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. The company offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.
The short version. GLAXOSMITH reported revenue of ₹1,184 crore for Sep 2026, up 20.8% from a year earlier. Net profit was ₹336 crore (up 30.7% year on year). Return on equity was 45.7% in Mar 2026. Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
GLAXOSMITH trades 15.1% below its 52-week high and 25.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,184 cr.
Sep 2026 net profit of ₹336 cr.
2.1 pts higher than a year earlier.
Revenue compounded at 5.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1184 | 938 | 995 | 1041 | 980 | 805 | 974 | 949 |
| Net profit | 336 | 237 | 278 | 296 | 257 | 205 | 263 | 230 |
| Net margin % | 28.4 | 25.3 | 27.9 | 28.4 | 26.3 | 25.5 | 27.0 | 24.2 |
| EPS (₹) | 19.83 | 14.0 | 16.4 | 17.45 | 15.2 | 12.1 | 15.52 | 13.57 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3822 | 3749 | 3454 | 3252 | 3278 | 3199 | 3224 | 3128 |
| Net profit | 1036 | 928 | 590 | 611 | 1695 | 358 | 93 | 445 |
| Net margin % | 27.1 | 24.7 | 17.1 | 18.8 | 51.7 | 11.2 | 2.9 | 14.2 |
| EPS (₹) | 61.15 | 54.75 | 34.83 | 36.05 | 100.04 | 21.14 | 5.5 | 26.29 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 45.7% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 45.7 | 47.5 | 33.2 | 35.1 |
| Return on capital % | 55.4 | 57.2 | 40.3 | 41.9 |
| EBITDA margin % | 37.2 | 34.1 | 24.8 | 27.0 |
| Net margin % | 26.1 | 23.8 | 16.5 | 18.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 5.8% | 3.7% |
| Profit CAGR | 19.3% | 23.7% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 0.25 pts over 8 quarters.
Up 1.18 pts over 8 quarters.
+32 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 0.0 |
| FII | 4.5 | 4.52 | 4.89 | 4.8 | 4.64 | 4.62 | 4.79 | 4.75 | +0.25 |
| DII | 7.3 | 7.79 | 7.7 | 7.75 | 7.7 | 7.68 | 7.8 | 8.48 | +1.18 |
| Public | 13.19 | 12.69 | 12.41 | 12.45 | 12.66 | 12.69 | 12.41 | 11.77 | -1.42 |
Mutual fund holdings · Oct 2026
144 schemes hold this stock
112 the month before.
- quant Healthcare Fund8.89% of NAV
- Bandhan Healthcare Fund3.07% of NAV
- quant Mid Cap Fund2.97% of NAV
- Baroda BNP Paribas Dividend Yield Fund2.83% of NAV
- NIPPON INDIA PHARMA FUND2.83% of NAV
- quant Dynamic Asset Allocation Fund2.61% of NAV
- DSP Nifty Midcap 150 Qlty 50 Index Fund2.35% of NAV
- DSP NIFTY MIDCAP 150 QUALITY 50 ETF2.35% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GLAXOSMITH are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about GLAXOSMITH
What is the GLAXOSMITH share price?
GLAXOSMITH (GLAXO) last closed at ₹2,714.00, up 2.87% on the day. Its 52-week range is ₹2,103.20 to ₹3,106.40.
What is the market cap of GLAXOSMITH?
GLAXOSMITH has a market capitalisation of about ₹44,689 crore. Its price-to-earnings ratio is 39.0.
How are GLAXOSMITH's latest results?
GLAXOSMITH reported revenue of ₹1,184 crore for Sep 2026, up 20.8% from a year earlier. Net profit was ₹336 crore (up 30.7% year on year). Return on equity was 45.7% in Mar 2026. Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.
Who owns GLAXOSMITH?
As of Sep 2026, shareholding was: Promoter 75.0%, FII 4.75%, DII 8.48%, Public 11.77%.
How many mutual funds hold GLAXOSMITH?
144 mutual fund schemes held GLAXOSMITH in October 2026. That compares with 112 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 May 2026 · Final Dividend - Rs. 57
- 30 May 2025 · Final Dividend - Rs. 42
- 07 Nov 2024 · Interim Dividend - Rs. 12
- 31 May 2024 · Final Dividend - Rs. 32
- 30 Jun 2023 · Final Dividend - Rs. 32
- 07 Jul 2022 · Special Dividend - Rs. 60
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.